This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Top Midday Stories: Return of 'Roaring Kitty' Lifts GameStop Shares; Intel, Apollo Near Deal on Ireland Plant; BHP Latest Offer Rejected by Anglo American; Squarespace Acquired by Permira; Amazon Autonomous Driving Under Probe MT
CAC40: symbolic losses, 'volat' rises at W-Street CF
Trending : Fulcrum Therapeutics, Sanofi in Losmapimod Licensing Deal DJ
Sartorius Partners With Sanofi for Biomanufacturing Platform MT
France Secures $16 Billion From Microsoft, Amazon and Others at Foreign Investment Summit -- 2nd Update DJ
France Secures $16 Billion From Microsoft, Amazon and Others at Foreign Investment Summit -- Update DJ
Fulcrum Therapeutics, Sanofi Sign Licensing Deal for Facioscapulohumeral Muscular Dystrophy Treatment MT
Sanofi to Invest $1.08 Billion Into Three French Drug Manufacturing Sites MT
Sanofi Signs License Deal for Rare Genetic Muscle Disease Drug MT
Sanofi to Invest $1.08 Billion Into 3 French Drug Manufacturing Sites MT
SANOFI : Sell rating from Deutsche Bank ZD
Fulcrum Therapeutics, Sanofi Ink Losmapimod Licensing Deal DJ
SANOFI : Berenberg maintains a Buy rating ZD
Regeneron, Sanofi Get Speedy FDA Review of Dupixent in Younger CRSwNP Group DJ
France Secures Billions at Foreign Investment Summit DJ
CAC40: stable at the start of a week packed with indicators CF
Regeneron Pharmaceuticals, Sanofi Say FDA Accepts Dupixent Supplemental Application for Priority Review MT
Sanofi to Spend $1.08 Billion to Boost Drug Production in France DJ
Sanofi invests 1.1 billion euros in France CF
Sanofi Plans EUR1 Billion Investments in France MT
Sanofi pledges new 1 bln euros worth of investments in French production sites RE
News Highlights : Top Company News of the Day - Friday at 7 PM ET DJ
Health Care Edges Higher Amid Rotation to Utilities - Health Care Roundup DJ
US Equity Markets Close Mixed Friday After Consumer Sentiment Falls MT
Sector Update: Health Care Stocks Higher Late Afternoon MT
Chart Sanofi
More charts
Sanofi is the largest European pharmaceutical group. Net sales by family of products break down as follows: - pharmaceutical products (70.6%): prescription drugs in the areas of specialty medicine (59.3% of net sales; for the treatment of multiple sclerosis, neurological diseases, inflammatory diseases, autoimmune diseases, rare diseases, cancers and rare hematological diseases) and general medicine (40.7%; mainly for the treatment of diabetes and cardiovascular diseases); - human vaccines (17.4%): pediatric vaccines, vaccines for flu, meningitis, and polio, booster vaccines, and vaccines for travelers and endemic areas; - consumer health products (12%). At the end of 2023, the group had 54 production sites throughout the world. Net sales are distributed geographically as follows: France (5.5%), Europe (18.6%), the United States (43%), North America (1.6%) and other (31.3%).
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
23
Last Close Price
94.33 EUR
Average target price
108.1 EUR
Spread / Average Target
+14.56%
Consensus
  1. Stock Market
  2. Equities
  3. SAN Stock
  4. News Sanofi
  5. Sanofi : Translate Bio Start Phase 1 Study to Test Influenza Vaccine
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW